Group 1: Stock Performance - Bristol Myers Squibb (BMY) stock closed at $53.78, showing a +1.34% change from the previous day's closing price, but lagged behind the S&P 500's daily gain of 9.52% [1] - The stock has decreased by 13.72% over the past month, which is worse than the Medical sector's loss of 14.16% and the S&P 500's loss of 13.47% [1] Group 2: Upcoming Earnings - The earnings report for Bristol Myers Squibb is anticipated on April 24, 2025, with expected earnings of $1.55 per share, reflecting a year-over-year growth of 135.23% [2] - Revenue is projected to be $10.69 billion, indicating a 9.94% decline from the same quarter last year [2] Group 3: Full Year Estimates - For the full year, earnings are estimated at $6.75 per share, representing a +486.96% change from the previous year, while revenue is projected at $45.59 billion, showing a -5.6% change [3] Group 4: Analyst Estimates - Recent changes in analyst estimates for Bristol Myers Squibb suggest a positive outlook on the company's business operations and profit generation capabilities [4] - The Zacks Rank system, which reflects these estimate changes, indicates a current rank of 3 (Hold) for Bristol Myers Squibb [6] Group 5: Valuation Metrics - Bristol Myers Squibb is currently trading at a Forward P/E ratio of 7.86, which is below the industry average Forward P/E of 15.86 [7] - The company has a PEG ratio of 1.97, compared to the industry average PEG ratio of 1.31, indicating a relatively higher valuation based on anticipated earnings growth [8] Group 6: Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [8][9]

Core Viewpoint - Bristol Myers Squibb (BMY) has received FDA approval for the label expansion of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a first-line treatment for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adult and pediatric patients aged 12 years and older [1][2] Company Developments - The latest FDA approval converts the previous accelerated approval for Opdivo monotherapy in the second-line setting to full approval and expands the indication for Opdivo plus Yervoy into the first-line treatment [2] - The approval was based on the phase III CheckMate-8HW study, which showed that Opdivo plus Yervoy met the dual primary endpoints of progression-free survival compared to Opdivo monotherapy and chemotherapy [4][5] - Opdivo plus Yervoy demonstrated a 79% reduction in the risk of disease progression or death compared to chemotherapy in the first-line setting and a 38% reduction versus Opdivo monotherapy across all lines of therapy [5] - The approval was granted more than two months ahead of the target action date of June 23, 2025, with ongoing studies assessing various secondary endpoints, including overall survival [6] Market Performance - BMY shares have increased by 7.9% over the past year, contrasting with a 20% decline in the industry [3] Portfolio Expansion - The approval of Opdivo continues to enhance BMY's immuno-oncology portfolio, with expectations for sustained impact into the next decade [7] - BMY's growth portfolio, which includes drugs like Reblozyl, Breyanzi, Camzyos, and Opdualag, has stabilized revenue amid generic competition for legacy drugs [10] - The company has also recently acquired 2seventy bio, Inc. for $286 million, sharing profits and losses related to the development of Abecma in the U.S. [12]

High-yielding dividend stocks can be great investments to hold on to in your portfolio, but only if they're safe. Betting on a high yield can be dangerous because if it ends up getting cut, you could lose all or most of the dividend income, and the stock may crash in the process as dividend investors could look elsewhere for a high payout. That's why it's always important to assess the safety of a dividend before relying on it, especially when that yield is well above average.Healthcare giant Bristol Myers ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has recommended approval of Opdivo (nivolumab) for another indication. The CHMP recommended approval of Opdivo in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by Opdivo as monotherapy as adjuvant treatment after surgical resection for the treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adult patient ...

Group 1: Bristol Myers Squibb - Bristol Myers Squibb is trading at a forward price-to-earnings (P/E) multiple of just 9, significantly lower than the S&P 500 average of 21 [2] - The company faces challenges such as multiple patent cliffs and a high long-term debt of $47.6 billion, compared to cash and marketable securities of $11.2 billion [3] - Despite risks, the company has secured approvals for two potential blockbuster drugs, Cobenfy and Breyanzi, which could generate substantial revenue [4] - The dividend payout ratio is 60%, supporting a 4% yield, making it attractive for dividend-focused investors [5] Group 2: United Parcel Service (UPS) - UPS has seen a 25% decline in stock price over the past year, resulting in a forward P/E multiple of less than 15 [6] - The company reported a profit of $5.8 billion on revenue of $91.1 billion last year, despite struggles in growth [7] - The payout ratio is around 100%, but free cash flow of $6.2 billion exceeds the $5.4 billion paid out in dividends, indicating a safe payout [8] - UPS offers a high yield of 5.7%, making it appealing for income investors [8] Group 3: Dell Technologies - Dell Technologies trades at a low forward P/E multiple of 10, with significant growth opportunities in artificial intelligence (AI) [9] - The server and networking business reported 54% sales growth in the most recent fiscal year [10] - The stock has a 2.2% dividend yield with a modest payout ratio of 28%, allowing for both dividend payments and growth investments [11]

Core Insights - The article emphasizes the importance of conducting personal in-depth research and due diligence before making investment decisions, highlighting the inherent risks involved in trading [3]. Group 1 - The analysis is intended solely for informational purposes and should not be interpreted as professional investment advice [3]. - There is a clear disclaimer regarding the lack of any stock, option, or derivative positions in the companies mentioned, indicating a neutral stance [2]. - The article expresses the author's personal opinions and does not reflect any business relationships with the companies discussed [2].

Core Insights - The article is part of a comparative analysis series focusing on pharmaceutical companies, specifically comparing Pfizer and Johnson & Johnson for investment potential [1] Group 1: Company Analysis - The analysis aims to evaluate which company presents a better investment opportunity for investors [1] Group 2: Research Background - Allka Research has over two decades of experience in investment, specializing in identifying undervalued assets across various sectors including pharmaceuticals [2] - The firm emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [2] - Allka Research seeks to empower investors by simplifying investment strategies and fostering a community of informed investors [2]

Core Viewpoint - Bristol Myers Squibb (BMY) is experiencing notable stock performance and is set to report earnings, with significant year-over-year changes anticipated in both earnings per share (EPS) and revenue [2][3]. Company Performance - BMY closed at $60.08, reflecting a +0.3% change from the previous session, while the S&P 500 gained 1.08% [1] - The stock has increased by 10.05% over the past month, outperforming the Medical sector's gain of 0.21% and the S&P 500's loss of 8.26% [1] Earnings Forecast - The upcoming earnings report on April 24, 2025, is expected to show an EPS of $1.55, representing a 135.23% increase from the same quarter last year [2] - Revenue is forecasted at $10.69 billion, which is a decrease of 9.94% from the prior-year quarter [2] Full-Year Estimates - The full-year Zacks Consensus Estimates predict earnings of $6.75 per share and revenue of $45.59 billion, indicating year-over-year changes of +486.96% and -5.6%, respectively [3] Analyst Estimates - Recent adjustments to analyst estimates for BMY reflect short-term business trends, with upward revisions indicating positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks BMY as 3 (Hold) [6] Valuation Metrics - BMY is trading with a Forward P/E ratio of 8.88, which is below the industry average of 19.17 [7] - The company has a PEG ratio of 2.22, compared to the industry average PEG ratio of 1.55 [7] Industry Context - BMY operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 73, placing it in the top 30% of over 250 industries [8]

Group 1 - The article identifies 10 undervalued dividend growth stocks for further research and potential investment, emphasizing their suitability for a dividend growth portfolio [1] - The candidates are ranked based on quality scores, highlighting their high quality and undervaluation [1] - The author, FerdiS, has over 20 years of investment and trading experience, focusing on dividend growth investing and options trading [1] Group 2 - FerdiS manages a portfolio named DivGro, primarily consisting of dividend growth stocks, established in January 2013 [1] - The article mentions collaboration with the founders of Portfolio Insight, an online platform for portfolio management and investment analysis [1] - Dividend Radar is maintained and published as a weekly free spreadsheet of dividend growth stocks [1]

Core Viewpoint - Bristol-Myers Squibb Company (NYSE: BMY) is recommended with a "Buy" rating due to its potential for stock price appreciation despite having high debt levels [1]. Group 1 - The coverage of Bristol-Myers Squibb was initiated in late March 2024 [1]. - The stock is expected to rise, indicating a positive outlook for investors [1]. - The analysis is provided by a chief investment analyst with extensive experience in navigating diverse investment information [1].